Prognosis
Moderna Set to Seek FDA Approval of Booster Against Omicron Variants
- Approval sought for shot that protects against new strains
- CDC scheduled to hold two-day meeting to discuss booster shots
Moderna Inc. Covid-19 vaccine booster shots.
Photographer: Toru Hanai/BloombergThis article is for subscribers only.
Moderna Inc. completed its filing to request U.S. clearance for a booster shot that targets the latest omicron Covid variants, a move to provide more protection against the persistent coronavirus.
In a statement, the company said it had wrapped up the submission for emergency authorization for the company’s bivalent Covid booster vaccine that targets the BA.4 and BA.5 strains along with the original version of Covid. The filing includes preclinical data for the booster against the latest strains, along with clinical data from the company’s other bivalent booster that targets the original omicron strain.